LIR Life Sciences and Neuland Laboratories announce a partnership to develop transdermal drug delivery systems for macromolecules, marking a significant step forward in their collaborative efforts as of May 22, 2026.

Neuland Labs reported a remarkable 135% revenue growth in Q4FY26, reaching ₹788.7 crore. Overall FY26 revenue increased by 37%. The EBITDA margin improved significantly in Q4FY26 to 40.5%, compared to 29.4% in FY26. However, the company faced a negative free cash flow of ₹49.4 crore due to higher working capital requirements.

Neuland Labs has given the green light for an increase in production capacity at Unit 1, indicating a potential growth in output for the company.

Neuland Labs has announced a dividend of INR 34 per share following the approval of their financial results for the fiscal year 2025-26. Additionally, they are planning a significant expansion of Unit 1's capacity, which will require an investment of approximately INR 143.4 crore over the next 12-18 months.

Neuland Labs has reported a remarkable 7-fold increase in their Q4 profits, reaching ₹213 crore, largely driven by a surge in export sales.

Goldman Sachs boosts Neuland Labs target price to INR 19,550, driven by robust Q4 CDMO performance and promising forecast of 40% EBITDA margins. Upgraded FY27-29 earnings estimates indicate an 8% increase due to enhanced pipeline, with a projected topline growth rate of over 20% for FY26-28.

Neuland Labs experienced a remarkable 665% increase in Q4 profit compared to last year, reaching INR 213 crores. Revenue grew by 136% YoY as well. The margin improved significantly to 39.6%. However, the company cautions that revenues from its CNS division are 'lumpy'.

Neuland Labs experienced a substantial profit increase in Q4, reaching approximately ₹2.1 billion compared to ₹278 million in the same quarter last year. Notably, their revenue more than doubled, climbing from ₹3.3 billion to ₹7.76 billion year-over-year.

Goldman Sachs boosts its price target for Neuland Labs to ₹19,550, maintaining a 'Buy' rating on the stock. The increase suggests growing optimism about the company's future prospects.

Neuland Labs' impressive Q4 results have caused a surge in interest, but potential investors should be aware of the company's warning about unpredictable earnings moving forward.

Neuland Labs, a company that has tripled its contract services revenue over the past three years, appoints Saharsh Davuluri as their new CEO and MD. The company aims to expand its peptide production capacity, following Davuluri's 18-year tenure with the firm.